Viewing Study NCT00724360


Ignite Creation Date: 2025-12-25 @ 2:11 AM
Ignite Modification Date: 2026-02-02 @ 1:01 AM
Study NCT ID: NCT00724360
Status: TERMINATED
Last Update Posted: 2013-10-07
First Post: 2008-07-25
Is NOT Gene Therapy: True
Has Adverse Events: False

Brief Title: Trastuzumab for HER2 Positive Relapsed/Refractory B-Acute Lymphoblastic Leukemia (B-ALL)
Sponsor: Nantes University Hospital
Organization:

Conditions & Keywords Data

Conditions:

Conditions

Condition Brief Condition Text View
None Relapsed/Refractory Leukemia View
Keywords:

Keywords

Keyword Brief Keyword Text View
None relapsed/refractory View
None HER2 View
None positive View
None B-ALL View
None trastuzumab View